Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Maintenance Post-BMT in Mantle Cell Lymphoma
NCT04402138Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by SCRI Development Innovations. Primary endpoint: Progression Free Survival Rate. Started Aug 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04402138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402138.